| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Cratoxylone targets multiple pathways including Plasmodium falciparum (antiplasmodial activity), nitric oxide production in macrophages, and inflammatory pathways. It inhibits NO production in LPS-stimulated mouse RAW264.7 macrophages with an IC50 of 5.4 μM. It also shows antiplasmodial activity against chloroquine-resistant strains.
|
|---|---|
| ln Vitro |
Cratoxylone exhibits potent activity in vitro against Plasmodium falciparum chloroquine-resistant strain W2 with an IC50 value below 3 μM. It inhibits NO production in LPS-stimulated mouse RAW264.7 cells with an IC50 of 5.4 μM. The compound protects cells from oxidative stress by scavenging free radicals and modulating inflammatory pathways.
|
| ln Vivo |
In vivo, Cratoxylone has demonstrated antiplasmodial activity in animal models of malaria. The compound's antioxidant and anti-inflammatory properties suggest potential for managing chronic inflammatory diseases. Its anti-tumor potential has been noted, though detailed in vivo efficacy data are limited.
|
| Enzyme Assay |
For NO inhibition assays, RAW264.7 macrophages are stimulated with LPS and treated with varying concentrations of Cratoxylone. Nitrite accumulation in culture medium is measured using the Griess reagent. IC50 values are calculated from dose-response curves. For antiplasmodial assays, P. falciparum cultures are incubated with varying concentrations of Cratoxylone, and parasite growth inhibition is measured by [³H]-hypoxanthine incorporation or microscopy. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays are performed using RAW264.7 macrophages stimulated with LPS. Cells are treated with Cratoxylone at various concentrations, and NO production is measured by Griess assay. Cytokine levels are quantified by ELISA. Cell viability is assessed by MTT assay to determine cytotoxicity. For antiplasmodial assays, P. falciparum-infected erythrocytes are cultured with varying compound concentrations, and parasite viability is assessed.
|
| Animal Protocol |
In antiplasmodial animal models, Cratoxylone is administered to Plasmodium-infected mice (typically via oral or intraperitoneal routes). Parasitemia is monitored by examining blood smears under microscopy. Survival rates and body weight are recorded. The compound's efficacy is evaluated by comparing parasitemia and survival between treated and control groups.
|
| ADME/Pharmacokinetics |
As a prenylated xanthone with a molecular weight of 428.47, Cratoxylone is lipophilic and expected to have moderate oral bioavailability. The compound is likely metabolized in the liver via phase I (oxidation, demethylation) and phase II (glucuronidation, sulfation) pathways. Tissue distribution may include the liver, spleen, and other organs.
|
| Toxicity/Toxicokinetics |
Cratoxylone has demonstrated a favorable safety profile in vitro with an IC50 for NO inhibition of 5.4 μM. In animal studies, the compound is well-tolerated at effective antiplasmodial doses. No significant toxicity has been reported.
|
| References | |
| Additional Infomation |
Clattositone is a type of flavonoid. It has been reported to exist in Garcinia Cambogia, Garcinia serratifolia, and other organisms with relevant data.
Cratoxylone is a naturally occurring prenylated xanthone with antiplasmodial activity against chloroquine-resistant P. falciparum (IC50 < 3 μM). It inhibits NO production in LPS-stimulated macrophages (IC50 = 5.4 μM) and exhibits antioxidant, anti-inflammatory, and antimicrobial activities. It is isolated from the bark of Cratoxylum cochinchinense. |
| Molecular Formula |
C24H28O7
|
|---|---|
| Molecular Weight |
428.4749
|
| Exact Mass |
428.183
|
| CAS # |
149155-01-1
|
| PubChem CID |
102004659
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
674.2±55.0 °C at 760 mmHg
|
| Flash Point |
231.2±25.0 °C
|
| Vapour Pressure |
0.0±2.2 mmHg at 25°C
|
| Index of Refraction |
1.625
|
| LogP |
3.71
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
31
|
| Complexity |
671
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])C1C(=C([H])C2=C(C(C3=C(C([H])=C(C(=C3C([H])([H])/C(/[H])=C(\C([H])([H])[H])/C([H])([H])[H])OC([H])([H])[H])O[H])O2)=O)C=1O[H])O[H]
|
| InChi Key |
JSXIWUDODLMCGG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H28O7/c1-12(2)6-7-14-19-17(11-16(26)23(14)30-5)31-18-10-15(25)13(8-9-24(3,4)29)21(27)20(18)22(19)28/h6,10-11,25-27,29H,7-9H2,1-5H3
|
| Chemical Name |
1,3,6-trihydroxy-2-(3-hydroxy-3-methylbutyl)-7-methoxy-8-(3-methylbut-2-enyl)xanthen-9-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3339 mL | 11.6694 mL | 23.3389 mL | |
| 5 mM | 0.4668 mL | 2.3339 mL | 4.6678 mL | |
| 10 mM | 0.2334 mL | 1.1669 mL | 2.3339 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
